Table 1.
Patients’ demographics and clinicopathological characteristics (n = 290)
| Age at diagnosis | Patients (n, %) |
|---|---|
| <40 | 7 (2.4) |
| 40-50 | 53 (18.3) |
| 51-60 | 71 (24.5) |
| >60 | 159 (54.8) |
| Diagnosis | |
| Invasive carcinoma (NST) | 208 (71.7) |
| ILC | 31 (10.7) |
| DCIS | 33 (11.4) |
| Other | 18 (6.2) |
| DCIS status* | |
| Invasive carcinomas without DCIS | 93 (36.3) |
| Invasive carcinomas with DCIS | 163 (63.7) |
| DCIS grade | |
| DCIS grade 1-2 | 77 (39.3) |
| DCIS grade 3 | 119 (60.7) |
| Hormone receptor status | |
| ER neg / pos / na | 44 (15.2) / 210 (72.4) / 36 (12.4) |
| PR neg / pos / na | 59 (20.3) / 122 (42.1) / 109 (37.6) |
| HER2 neg / pos / na | 215 (74.1) / 40 (13.8) / 35 (12.1) |
| Tumor size | |
| ≤20 mm | 159 (62.1) |
| 21- 50 mm | 87 (34.0) |
| >50 mm | 10 (3.9) |
| Histological grade* | |
| 1 | 85 (33.3) |
| 2 | 121 (47.5) |
| 3 | 49 (19.2) |
| Lymph node involvement | |
| Negative | 204 (70.3) |
| Positive | 86 (29.7) |
| Involved lymph nodes | |
| 1-3 | 62 (72.1) |
| >3 | 24 (27.9) |
| Immune cell infiltration* | |
| No infiltration | 39 (13.5) |
| Mild infiltration | 144 (49.8) |
| Moderate infiltration | 90 (31.1) |
| Extensive infiltration | 16 (5.6) |
| Aggregate formation* | |
| Negative | 143 (49.5) |
| Positive | 146 (50.5) |
| TLS formation* | |
| Negative | 175 (61.4) |
| Positive | 110 (38.6) |
Abbreviations: NST invasive carcinoma of no special type, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, other invasive carcinomas include: tubular carcinoma, cribriform carcinoma, mucinous carcinoma, medullary carcinoma, apocrine carcinoma, metaplastic carcinoma, papillary carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TLS tertiary lymphoid structures, na not analysed. *Patient(s) data missing.